Related Experiment Videos
[NSAIDs and COX-2-inhibitors: current status]
1Schwerpunkt Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik II der Universität, Würzburg. Kneitz_C@klinik.uni-wuerzburg.de
Der Internist
|March 25, 2006
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors effectively manage joint pain but carry risks. Individualized risk assessment and lowest effective dosage are crucial for safe NSAID and COX-2 inhibitor use.
Area of Science:
- Pharmacology
- Rheumatology
- Gastroenterology
Context:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for inflammatory and degenerative joint diseases.
- NSAIDs present significant gastrointestinal (GI) side effects, necessitating safer alternatives.
- Selective COX-2 inhibitors offer improved GI safety, particularly for high-risk patients.
Purpose:
- To evaluate the therapeutic efficacy and safety profiles of NSAIDs and selective COX-2 inhibitors.
- To compare the gastrointestinal safety of COX-2 inhibitors with NSAIDs, including combination therapy.
- To assess the cardiovascular risks associated with COX-2 inhibitors and conventional NSAIDs.
Summary:
- Selective COX-2 inhibitors demonstrate better gastrointestinal safety than traditional NSAIDs, reducing ulcer and bleeding risks.
- Combining NSAIDs with proton pump inhibitors may offer similar gastrointestinal protection.
- Both COX-2 inhibitors and conventional NSAIDs are associated with an elevated risk of myocardial infarction, requiring careful individual risk assessment.
Impact:
- Highlights the need for personalized risk-benefit analysis before prescribing NSAIDs or COX-2 inhibitors.
- Recommends using the lowest effective dosage for the shortest possible duration.
- Suggests further research to define risk factors and optimize treatment strategies for NSAIDs and COX-2 inhibitors.